| scholarly article | Q13442814 |
| P50 | author | Traci Rieckmann | Q47378631 |
| P2093 | author name string | Anne E Kovas | |
| Beth A Rutkowski | |||
| P2860 | cites work | Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence | Q24248675 |
| Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation | Q28140216 | ||
| Mortality and morbidity attributable to use of addictive substances in the United States | Q28142616 | ||
| Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders | Q29615543 | ||
| Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors | Q31041707 | ||
| Innovations in mental health services implementation: a report on state-level data from the U.S. Evidence-Based Practices Project | Q31042689 | ||
| The economic costs of heroin addiction in the United States | Q31799483 | ||
| Pharmacological treatment of alcohol dependence: a review of the evidence | Q33596810 | ||
| Client and counselor attitudes toward the use of medications for treatment of opioid dependence | Q33763021 | ||
| Partnerships and pathways of dissemination: the National Institute on Drug Abuse-Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network | Q33793165 | ||
| Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals | Q33837582 | ||
| The gap between research and practice in substance abuse treatment | Q46554699 | ||
| Buprenorphine diffusion: the attitudes of substance abuse treatment counselors | Q46680941 | ||
| A national study of the substance abuse treatment workforce | Q48025234 | ||
| Assessing organizational readiness for change | Q48631182 | ||
| The state policy context of implementation issues for evidence-based practices in mental health | Q50152633 | ||
| A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. | Q51502804 | ||
| Implementation of evidence-based practice in community behavioral health: agency director perspectives. | Q51901423 | ||
| Challenges to implementing and sustaining comprehensive mental health service programs. | Q51918485 | ||
| The role of state mental health authorities in promoting improved client outcomes through evidence-based practice. | Q51926457 | ||
| Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. | Q52276189 | ||
| A 3-year progress report on the implementation of LAAM in the United States. | Q52276193 | ||
| Technology transfer and the treatment of addiction: what can research offer practice? | Q52281178 | ||
| Improving continuity of care in a public addiction treatment system with clinical case management. | Q52288413 | ||
| Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. | Q52894361 | ||
| The federal role in drug abuse technology transfer: a history and perspective. | Q53430425 | ||
| Naltrexone and coping skills therapy for alcohol dependence. A controlled study | Q67587951 | ||
| A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse | Q73230281 | ||
| A conceptual framework for transferring research to practice | Q74318938 | ||
| Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction | Q77675795 | ||
| Does state certification or licensure influence outpatient substance abuse treatment program practices? | Q80529895 | ||
| Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience | Q34081656 | ||
| Efficacy and tolerability of naltrexone in the management of alcohol dependence | Q34116140 | ||
| Naltrexone in the treatment of alcohol dependence | Q34241680 | ||
| Comparing overdose mortality associated with methadone and buprenorphine treatment | Q34607700 | ||
| Buprenorphine tapering schedule and illicit opioid use. | Q35147170 | ||
| Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty | Q35195803 | ||
| Controlled trials of Antabuse in alcoholism: the importance of supervision and adequate dosage | Q35625495 | ||
| The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters | Q35792939 | ||
| Direct costs of opioid abuse in an insured population in the United States | Q36184100 | ||
| Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs | Q36213324 | ||
| Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network. | Q36627877 | ||
| Buprenorphine for acute heroin detoxification: diffusion of research into practice | Q36738505 | ||
| State policy influence on the early diffusion of buprenorphine in community treatment programs | Q36766544 | ||
| Implementation of evidence-based practices for treatment of alcohol and drug disorders: the role of the state authority | Q36884533 | ||
| Methadone maintenance treatment in opiate dependence: a review. | Q36887595 | ||
| Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial | Q37030355 | ||
| Research on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review | Q37224883 | ||
| Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report | Q37331386 | ||
| The state of pharmacotherapy for the treatment of alcohol dependence | Q37343267 | ||
| Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. | Q37352259 | ||
| Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption | Q37352521 | ||
| Impact of substance disorders on medical expenditures for medicaid beneficiaries with behavioral health disorders | Q37359814 | ||
| Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment | Q37756209 | ||
| Treatment of heroin dependence with buprenorphine in primary care | Q39602688 | ||
| A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence | Q43593858 | ||
| Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes | Q43798723 | ||
| Adoption and implementation of new technologies in substance abuse treatment. | Q44033265 | ||
| 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial | Q44328541 | ||
| Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective | Q44332113 | ||
| High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans | Q44338361 | ||
| The underrecognized toll of prescription opioid abuse on young children | Q44340035 | ||
| A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. | Q44342350 | ||
| The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? | Q44349305 | ||
| Research to practice: adoption of naltrexone in alcoholism treatment | Q44368411 | ||
| Buprenorphine versus methadone maintenance: a cost-effectiveness analysis | Q44574571 | ||
| Training rural practitioners to use buprenorphine; using The Change Book to facilitate technology transfer | Q44829776 | ||
| Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication | Q44875497 | ||
| Adoption of naltrexone to treat alcohol dependence | Q46460780 | ||
| P921 | main subject | substance abuse | Q3184856 |
| P304 | page(s) | 227-238 | |
| P577 | publication date | 2010-09-01 | |
| P1433 | published in | Journal of Psychoactive Drugs | Q6295808 |
| P1476 | title | Adoption of medications in substance abuse treatment: priorities and strategies of single state authorities | |
| P478 | volume | Suppl 6 |
| Q37580421 | Adoption and diffusion of evidence-based addiction medications in substance abuse treatment |
| Q35490468 | Barriers to use of pharmacotherapy for addiction disorders and how to overcome them |
| Q38838575 | Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study |
| Q37638165 | Establishing the feasibility of measuring performance in use of addiction pharmacotherapy |
| Q36381418 | Financial factors and the implementation of medications for treating opioid use disorders |
| Q34404288 | Improving treatment for opioid dependence: a perspective from the Ohio Valley node of the NIDA Clinical Trials Network. |
| Q36192673 | Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders |
| Q30373948 | Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: Data from a national sample of treatment organizations |
| Q37729027 | The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources |
| Q35204253 | Views about responsibility for alcohol addiction and negative evaluations of naltrexone |
Search more.